About Asarina Pharma
Asarina Pharma is a company based in Umea (Sweden) founded in 2006. It operates as a HealthTech. Asarina Pharma has raised $28.01 million across 4 funding rounds from investors including Handelsbanken, Idinvest Partners and Ergomed. The company has 1 employees as of August 31, 2024. Asarina Pharma offers products and services including Sepranolone. Asarina Pharma operates in a competitive market with competitors including Agile Therapeutics, Auxilium Pharmaceuticals, Xanodyne Pharmaceuticals, Microchips Biotech and Marius Pharmaceuticals, among others.
- Headquarter Umea, Sweden
- Employees 1 as on 31 Aug, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Asarina Pharma Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$28.01 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
Handelsbanken
& 7 more
-
Employee Count
1
as on Aug 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Asarina Pharma
Asarina Pharma offers a comprehensive portfolio of products and services, including Sepranolone.
Sepranolone is developed for neuroendocrinological disorder treatment.
Funding Insights of Asarina Pharma
Asarina Pharma has successfully raised a total of $28.01M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Asarina Pharma
Asarina Pharma has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Handelsbanken, Idinvest Partners and Ergomed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research funding is provided for Baltic and Eastern European studies.
|
Locked | Locked | Locked | |
|
Equity investments are provided to low and middle market companies.
|
Locked | Locked | Locked | |
|
Early-stage life science investments in Sweden are targeted.
|
Locked | Locked | Locked |
Investor details for Asarina Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Asarina Pharma
Investment portfolio details for Asarina Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Asarina Pharma
Detailed financials for Asarina Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Asarina Pharma Comparisons
Peer comparison for Asarina Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Asarina Pharma
Asarina Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Agile Therapeutics, Auxilium Pharmaceuticals, Xanodyne Pharmaceuticals, Microchips Biotech and Marius Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for women's healthcare are developed and offered.
|
|
| Locked | Locked | Locked |
Developer of therapeutics and drug-device combinations for urology and sexual health
|
|
| Locked | Locked | Locked |
Developer of drugs for women's health and pain management
|
|
| Locked | Locked | Locked |
Microchip implants for wireless drug delivery are developed.
|
|
| Locked | Locked | Locked |
A proprietary oral testosterone replacement therapy platform is developed.
|
Detailed competitors of Asarina Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Asarina Pharma
Complete news archive for Asarina Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Asarina Pharma
Asarina Pharma was founded in 2006 and raised its 1st funding round 7 years after it was founded.
Asarina Pharma is headquartered in Umea, Sweden.
Peter Nordkild is the current CEO of Asarina Pharma.
Asarina Pharma is a funded company, having raised a total of $28.01M across 4 funding rounds to date.
As of Aug 31, 2024, the latest employee count at Asarina Pharma is 1.
Asarina Pharma, a Swedish biotech company, is engaged in the development of Sepranolone for treating Allopregnanolone-related stress, compulsion, menstrual, and neurological disorders. The company operates in the healthcare sector, specifically biotechnology, targeting neuroendocrinological conditions. Its solutions are built on over 40 years of research into Allopregnanolone-related disorders, with a new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) aimed at delivering efficacious and safe drugs for widely untreated conditions such as Tourette Syndrome, OCD, and PMDD. Research and clinical trials, including Phase IIa studies, are conducted to validate the safety and efficacy of its pharmaceutical offerings.
Asarina Pharma's top competitors include Agile Therapeutics, Auxilium Pharmaceuticals and Marius Pharmaceuticals.
Asarina Pharma offers Sepranolone.
Asarina Pharma has 8 investors. Key investors include Handelsbanken, Idinvest Partners, Ergomed, Karolinska Development, and Fjarde AP-fonden.